Perspectives on Ulcerative Colitis in Europe
Publicado el 15/12/2017 a las 10:20
Visitas: [ 231 ]
Autores; Dr. Panés y Dr. González Lama
Topic Information
Goal Statement
The goal of the 2016-2017 Xpert Perspectives on Ulcerative Colitis in Europe On-Demand Series is to deliver focused updates highlighting the most clinically relevant advances in treatment decisions for patients with UC throughout Europe.
Target Audience
The target audiences for this initiative are gastroenterologists, specialist nurses and general practitioners. Siyemi and the GiHF believe this program will enhance the professional effectiveness of program participants of treating their patients with ulcerative colitis, benefiting patients under their care.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Develop strategies to select the optimal therapeutic goal and treatment choices for UC
Describe the effect that UC has on patient quality of life
Implement strategies for incorporating recently approved and emerging therapies for UC
Define biosimilars and discuss the scientific concept, real world data and benefits
Analyze recently approved and emerging therapies for UC
Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and GI Health Foundation.
Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians. Siyemi Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: June 6th, 2017
Expiration Date: June 6th, 2018
Disclosure statement
Yago González Lama, MD:
Advisory Board: Janssen and AbbVie
Speaker: Pfizer, Janssen, AbbVie and Takeda
Honorarium Recipient: Shire
Julian Panes, MD:
Consultant: AbbVie, Boehringer-Ingelheim, Celgene, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Secon Genome, Takeda and TiGenix
Grant Recipient: AbbVie and MSD
Speakers' Bureau: Ferring, Pfizer, Janssen, MSD
All staff at Siyemi Learning and GiHF have no relevant financial relationships to disclose.
The goal of the 2016-2017 Xpert Perspectives on Ulcerative Colitis in Europe On-Demand Series is to deliver focused updates highlighting the most clinically relevant advances in treatment decisions for patients with UC throughout Europe.
Target Audience
The target audiences for this initiative are gastroenterologists, specialist nurses and general practitioners. Siyemi and the GiHF believe this program will enhance the professional effectiveness of program participants of treating their patients with ulcerative colitis, benefiting patients under their care.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Develop strategies to select the optimal therapeutic goal and treatment choices for UC
Describe the effect that UC has on patient quality of life
Implement strategies for incorporating recently approved and emerging therapies for UC
Define biosimilars and discuss the scientific concept, real world data and benefits
Analyze recently approved and emerging therapies for UC
Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and GI Health Foundation.
Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians. Siyemi Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: June 6th, 2017
Expiration Date: June 6th, 2018
Disclosure statement
Yago González Lama, MD:
Advisory Board: Janssen and AbbVie
Speaker: Pfizer, Janssen, AbbVie and Takeda
Honorarium Recipient: Shire
Julian Panes, MD:
Consultant: AbbVie, Boehringer-Ingelheim, Celgene, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Secon Genome, Takeda and TiGenix
Grant Recipient: AbbVie and MSD
Speakers' Bureau: Ferring, Pfizer, Janssen, MSD
All staff at Siyemi Learning and GiHF have no relevant financial relationships to disclose.
Última actualización: 15/10/2021
Asociación Española de Gastroenterología
C/ Sor Ángela de la Cruz, 8, 1ºA
28020 Madrid
secretaria@aegastro.es
Tel. 91 555 11 19
Fax. 91 555 35 81